Dr. Tom Fogarty,
World Renowned Surgeon / Inventor
M.D - Founder and Consulting Engineer
Tom Fogarty, former Stanford University Professor and cardiovascular surgeon has founded over 33 medical device companies and along the way is credited with over 125 patents. It has been estimated that Dr. Fogarty’s medical devices have touched the lives of over 25 million patients worldwide.
The founding of Crux Biomedical in 2004 was another step in Fogarty’s passion to provide clinicians with improved medical treatments for potentially life threatening conditions of the human vascular system.
Considered one the most prolific medical device inventors, his invention of the Fogarty Balloon Catheter in the 1950’s gave physicians a new tool to remove potentially fatal blood clots from arteries, without surgery. This invention is credited by many with helping start the field of interventional medicine, where catheters deliver new treatments in a less invasive manner.
His AneuRx® Stent Graft, approved by the FDA in 2000, provided patients the first non-surgical treatment alternative for abdominal aortic aneurysms, (a bulge or weakening of the arterial wall of the aorta). Over 50,000 patients have benefited from this life saving medical implant.
The inventive genius of Tom Fogarty has been widely recognized. In 2000, he received the prestigious Lemelson-MIT prize for Invention and Innovation. He was inducted into the National Inventors Hall of Fame in 2001
Doug is a general partner at Alloy Ventures, a leading venture capital firm in Silicon Valley. The partners of the firm have helped start and cultivate more than 200 information technology and life science companies going back to 1977. The firm has over $1 Billion under management. Prior to Alloy, he was an early employee at Ligand Pharmaceuticals, and worked for 2 European venture capital firms. Aside from Crux, Doug was an early investor in Fusion (Baxter), Sapient Health Network (WebMD); Integrated Biosystems (Sartorius/Stedim), Camitro (Arqule), Pharsight (Tripos); and Adiana (Hologic). He is currently on the boards and/or an early investor in Aegea, Barrx, Cameron Health, CoAlign, KaloBios, Novasys, and Restoration Robotics. He holds a BA in Biochemistry/Molecular Engineering from Univ. of California, San Diego, an MD from Albert Einstein College of Medicine and an MBA from Stanford University, where he teaches Business 16, “Financing the Start-Up”
Mr. Lindholm is a widely respected advisor to the medical device field. He was previously Chairman and CEO of Vidamed, a maker of minimally invasive medical devices to treat benign prostate hyperplasia until it was acquired by Medtronic in 2002. Prior to Vidamed, Randy held senior positions at Nellcor Puritan Bennett and GE Medical Systems. He currently serves as director of publically held Omnicell (MLCL), Barrx Medical, Tibion Bionic Technologies, Estech and Novasys Medical.
Rod joined Three Arch Partners as a Venture Partner in May 2006. Prior to Three Arch Partners, Rod was President and CEO of Vivant Medical, a Three Arch Partners medical device company that was acquired by Tyco, President & CEO of Targesome, Chairman & CEO of General Surgical Innovations, also a Three Arch Partners medical device company that was acquired by Tyco, President & CEO of Focus Surgery, President of Toshiba America MRI, and President & COO of Diasonics.
Rod holds a BS degree in Industrial Engineering from Stanford University and an MBA from The Harvard Business School.
Mel Schatz (See Management Team)